Brief: Sol Gel Technologies Ltd Phase 3 Trial Of Sgt-610 For Gorlin Syndrome Is Ongoing,Top-Line Results Expected Q4 2026
20/11/2025 13:14
Sol Gel Technologies Ltd SLGL.O: SOL GEL TECHNOLOGIES LTD: PHASE 3 TRIAL OF SGT-610 FOR GORLIN SYNDROME IS ONGOING,TOP-LINE RESULTS EXPECTED Q4 2026 SOL GEL TECHNOLOGIES LTD: EXPECTS ITS CASH RESOURCES TO FUND CASH REQUIREMENTS INTO Q1 OF 2027 Source text: ID:nGNX1Y3Wwl Further company coverage: SLGL.O
Recent news on SOL-GEL TECHNOLOGIES
See all newsIsraeli dermatology firm Sol-Gel's Q2 revenue drops sharply on prior-year IP sale
SOL-GEL TECHNOLOGIES LTD. expected to post a loss of $2.57 a share - Earnings Preview
Sol-Gel Q1 revenue falls sharply on milestone payment impact
Brief: Sol-Gel Technologies Ltd. Q1 Revenue USD 100 Thousand
Brief: Sol-Gel Technologies Ltd. Announces Pricing Of Oversubscribed Underwritten Offering